TY - JOUR
T1 - Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms
AU - Gudayol-Ferré, Esteve
AU - Herrera-Guzmán, Ixchel
AU - Camarena, Beatriz
AU - Cortés-Penagos, Carlos
AU - Herrera-Abarca, Jorge E.
AU - Martínez-Medina, Patricia
AU - Asbun-Bojalil, Juan
AU - Lira-Islas, Yuridia
AU - Reyes-Ponce, Celia
AU - Guàrdia-Olmos, Joan
PY - 2012/11
Y1 - 2012/11
N2 - Objective The aim of our work is to study the possible role of clinical variables, neuropsychological performance, and the 5HTTLPR, rs25531, and val108/58Met COMT polymorphisms on the prediction of depression remission after 12 weeks' treatment with fluoxetine. These variables have been studied as potential predictors of depression remission, but they present poor prognostic sensitivity and specificity by themselves. Methods Seventy-two depressed patients were genotyped according to the aforementioned polymorphisms and were clinically and neuropsychologically assessed before a 12-week fluxetine treatment. Results Only the La allele of rs25531 polymorphism and the GG and AA forms of the val 108/158 Met polymorphism predict major depressive disorder remission after 12 weeks' treatment with fluoxetine. None of the clinical and neuropsychological variables studied predicted remission. Conclusions Our results suggest that clinical and neuropsychological variables can initially predict early response to fluoxetine and mask the predictive role of genetic variables; but in remission, where clinical and neuropsychological symptoms associated with depression tend to disappear thanks to the treatment administered, the polymorphisms studied are the only variables in our model capable of predicting remission. However, placebo effects that are difficult to control require cautious interpretation of the results.
AB - Objective The aim of our work is to study the possible role of clinical variables, neuropsychological performance, and the 5HTTLPR, rs25531, and val108/58Met COMT polymorphisms on the prediction of depression remission after 12 weeks' treatment with fluoxetine. These variables have been studied as potential predictors of depression remission, but they present poor prognostic sensitivity and specificity by themselves. Methods Seventy-two depressed patients were genotyped according to the aforementioned polymorphisms and were clinically and neuropsychologically assessed before a 12-week fluxetine treatment. Results Only the La allele of rs25531 polymorphism and the GG and AA forms of the val 108/158 Met polymorphism predict major depressive disorder remission after 12 weeks' treatment with fluoxetine. None of the clinical and neuropsychological variables studied predicted remission. Conclusions Our results suggest that clinical and neuropsychological variables can initially predict early response to fluoxetine and mask the predictive role of genetic variables; but in remission, where clinical and neuropsychological symptoms associated with depression tend to disappear thanks to the treatment administered, the polymorphisms studied are the only variables in our model capable of predicting remission. However, placebo effects that are difficult to control require cautious interpretation of the results.
KW - 5HTTLPR
KW - COMT
KW - antidepressant response
KW - major depressive disorder
KW - neuropsychological assessment
KW - polymorphism
UR - http://www.scopus.com/inward/record.url?scp=84868552801&partnerID=8YFLogxK
U2 - 10.1002/hup.2267
DO - 10.1002/hup.2267
M3 - Artículo
SN - 0885-6222
VL - 27
SP - 577
EP - 586
JO - Human Psychopharmacology
JF - Human Psychopharmacology
IS - 6
ER -